1.Кан Д.В., Сегал А.С., Кузьменко А.Н. Диагностика и лечение хронического неспецифического простатита. Методические рекомендации. М., 1980; с. 30.2.Тиктинский О.Л. Воспалительные заболевания мочеиспускательного канала, предстательной железы, семенных пузырьков и семенного бугорка.3.Руководство по андрологии. Л., 1990; с. 54–97.4.Лопаткин Н.А. Руководство по урологии. 1998; 2: 393–440.5.Moon T.D. Diagnostic and treatment practices for prostatitis by urologists and primary care physicians. J Urol 1997; 157: 242A.6.Collins M.M., Stafford R.S., O\'Leary M.P., Barry M.J. How common is prostatitis? A national survey of physician visits. J Urol 1998; 159: 1224–8.7.Nickel J.C. Prostatitis: myths and realities. Urology 1998; 51: 362–6.8.Schaeffer A.J., Anderson, Krieger J.N. et al. WHO Consultation, Paris 2005.9.Krieger J.N., Nyberg L, Nickel J.C. NIH consensus definition and classification of prostatitis. JAMA 1999; 281: 236–7.10.Wagenlehner F.M., Naber K.G. Prostatitis: the role of antibiotic treatment. World J Urol 2003; 21 (2): 105–8.11.Meares E.M., Stamey T.A. Bacteriological localization patterns in bacterial prostatitis and uretritis. Invest Urol 1968; 5: 492–518.12.Nickel J.C., Shoskes D, Wang Y et al. How does the pre - massage and post - massage 2 - glass test compare to the Meares - Stamey 4 -glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol 2006; 176: 119–24.13.Schaeffer A.J., Weidner W, Barbalis G.A. Summary Consensus Statement: Diagnosis and Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Eur Urol 2003; Suppl. 2: 1–4.14.Pavone-Macaluso M. Chronic prostatitis syndrome: a common, but poorly understood condition. Part I. EAU - EBU update series 2007; 5: 1–15.15.Naber K.G., Weidner W. Chronic prostatitis – an infectious disease? J Antimicrob Chemother 2000; 46: 157–61.16.Naber K.G., Busch W, Focht J, the German Prostatitis Study Group. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, noncomparative multicentre clinical trial with long - term follow - up. Int J Antimicrob Agents 2000; 14: 143–9.17.Krieger J.N., Ross S.O., Limaye A.P., Riley D.E. Inconsistent localisation of grampositive bacteria to prostate - specific specimens from patients with chronic prostatitis. Urology 2005; 66: 721–5.18.Weidner W, Diemer T, Huwe P et al. The role of Chlamydia trachomatis in prostatitis. Int J Antimicrob Agents 2002; 19: 466–70.19.Weidner W, Schiefer H.G., Kraus H et al. Chronic prostatitis a through search for etiologically involved microorganisms in 1461 patients. Infection 1991;19 (suppl. 3): 119–25.20.Лоран О.Б., Пушкарь Д.Ю., Сегал А.С., Юдовский С.О. Наше понимание хронического простатита. Фарматека. 2002; 10: 69–75.21.Naber K.G. Role of quinolones in treatment of chronic bacterial prostatitis. Quinolone Antimicrobial Agents. Eds. D.C.Hooper, J.Wolfson – American Society for Microbiology. Washington D.C. USA, 1993; p. 285–97.22.Naber K.G., Sorgel F. Antibiotic therapy – rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003; 35 (5): 331–5.23.Pavone-Macaluso M. Chronic prostatitis syndrome: a common, but poorly understood condition. Part II. EAU-EBU update series 2007; 5: 16–25.24.Naber K.G., Bishop M.C., Bjerklund-Johansen T.E. et al. Guidelines on the management of urinary and male genital tract infections. Eur Assoc of Urology. 2006.25.Drusano G.L.,. Preston S.L., Van Guilder M et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000; 44 (8): 2046–51.26.Trinchiere A. Role of levofloxacin in the treatment of urinary tract infections. Arch Ital Urol Androl 2001; 73 (2): 105–13.27.Croom K.F., Goa K.L. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63 (24): 2768–802.28.Naber K.G. Levofloxacin in the treatment of urinary tract infection and prostatitis. J Chemother 2004; 16 (Suppl. 2): 18–21.29.Bulitta J, Kinzig-Schippers M, Naber C.K. et al. Limitations in the use of drug cocktails to compare the pharmacokinetics of drugs: ciprofloxacin versus levofloxacin. 40th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), Toronto, Canada, 17–20 September 2000 (poster no. 506). Bundrick W, Heron S.P., Ray P et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double - blind multicenter study. Urology 2003; 62 (3): 537–41.30.Мазо Е.Б., Ковальчук Л.В., Ганковская Л.В. и др. Эффективность применения Суперлимфа в комплексном лечении хронического бактериального простатита и воспалительного синдрома хронической тазовой боли. Материалы 3-й Всероссийской конференции «Мужское здоровье». М., 2006; с. 72–3.31.Naber K.G., Roscher K, Botto H, Schaefer V. Oral levofloxacin 500mg once daily in the treatment of chronic bacterial prostatitis. International J Antimicrob Agents 2008 Jun 19. [Epub ahead of print]32.Giannarini G, Mogorovich A, Morelli G et al. Chronic bactierial prostatitis: a prosective, randomized, double - blinde triale. AUA Annual Meeting, Anaheim May 19–24, 2007 (abstr. 99).33.Jeong C.W., Lim D.J., Son H et al. Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. Urol Int 2008; 80 (2): 157–61.34.Tal R et al. Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy. J Urol 2003; 169: 1762–5.35.Shigehara K, Miyagi T, Nakashima T, Shimamura M. Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis. J Infect Chemother 2008; 14 (1): 40–3. Epub 2008 Feb 24.36.Briffaux R et al. One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography - guided prostate biopsy. BJU International 2008; 103: 1069–73.37.Hoshi A et al. Sepsis following transrectal prostate biopsy: a report of 2 cases and reviewed similar cases in Japan. Hinyokika Kiyo 2006; 52 (8): 645–9.38.Miura T, Tanaka K, Shigemura K et al. Levofloxacin resistant Escherichia coli sepsis following an ultrasound - guided transrectal prostate biopsy: report of four cases and review of the literature. Int J Urol 2008; 15 (5): 457–9.39.Scotton P.G. et al. Which antibiotic prophylaxis to use for urologic procedures at risk for infective endocarditis: a report on two cases. Infez Med 2006; 14 (4): 246–7.40.Feliciano J, Teper E, Ferrandino M et al. The incidence of fluoroquinolone resistant infections after prostate biopsy – are fluoroquinolones still effective prophylaxis? J Urol 2008; 179 (3): 952–5.41.Griffith B.C., Morey A.F., Ali-Khan M.M. et al. Single dose levofloxacin prophylaxis for prostate biopsy in patients at low risk. J Urol 2002; 168 (3): 1021–3.42.Берников А.Н., Раснер П.И., Говоров А.В., Бормотин А.В. Профилактическая антибактериальная терапия при трансректальной биопсии предстательной железы. Фарматека. 2002; 10: 59–60.43.Говоров А.В., Пушкарь Д.Ю, Зайцев А.В., Курджиев М.А. Антибактериальная профилактика левофлоксацином при трансректальной биопсии предстательной железы – новый стандарт? Материалы Всероссийской научно - практической конференции «Современные принципы диагностики, профилактики и лечения инфекционно - воспалительных заболеваний почек, мочевыводящих путей и половых органов». М., 8–9 февраля 2007; с. 34–5.44.Yamamoto S, Ishitoya S, Segawa T et al. Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin. Int J Urol 2008; 15 (7): 604–6.